Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
CONCLUSION: Long-term MOGCT survivors treated with CBCT have small but significant reductions in age-adjusted hearing thresholds at 4, 6 and 8kHz versus Controls. Approximately one in four women experienced subjective hearing loss. To avoid overestimation of clinically relevant cisplatin-induced ototoxicity, absolute hearing thresholds should be age-adjusted and compared to an age-matched control group.
PMID: 28202195 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Skalleberg J, Solheim O, Fosså SD, Småstuen MC, Osnes T, Gundersen PO, Bunne M Tags: Gynecol Oncol Source Type: research
More News: Audiometry | Cancer | Cancer & Oncology | Chemotherapy | Germ Cell Tumors | Ovarian Cancer | Ovaries | Tinnitus | Women